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The brain histaminergic system is one of the diffuse modulatory neurotransmitter systems
which regulate neuronal activity in many brain areas. Studies on both rats andmice indicate
that histamine H3 receptor antagonists decrease alcohol drinking in several models, like
operant alcohol administration and drinking in the dark paradigm. Alcohol-induced place
preference is also affected by these drugs. Moreover, mice lacking H3R do not drink alco-
hol like their wild type littermates, and they do not show alcohol-induced place preference.
Although the mechanisms of these behaviors are still being investigated, we propose that
H3R antagonists are promising candidates for use in human alcoholics, as these drugs are
already tested for treatment of other disorders like narcolepsy and sleep disorders.
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INTRODUCTION
Alcohol dependence is a remarkable health risk for the society.
More than 60 diseases and injuries resulting in approximately 2.5
million deaths per year worldwide are linked to heavy alcohol
drinking (Edwards et al., 2011). The number of current available
medications for the treatment of alcohol dependence is limited,
and most treatments show only moderate efﬁcacy. Promising
results in the treatment of alcohol dependence have been obtained
with some existing drugs such as anti-epileptic drug topiramate,
antispasmic baclofen, and nausea relieving ondansetrone (Sellers
et al., 1994;Addolorato et al., 2002; Johnson et al., 2003). New ther-
apeutic drug targets have also been launched during the last years
including cannabinoid receptors, neuropeptide Y, corticotropin-
releasing factor, and ghrelin (Kraus et al., 2005; Thorsell et al.,
2006; Lowery and Thiele, 2010;Maccioni et al., 2010). Recent ﬁnd-
ings from our laboratory using various animal models assessing
dependence-like alcohol behaviors as well as binge-like alcohol
drinking suggest that histamine H3 receptor could be a poten-
tial therapeutic target in the treatment of alcohol dependence
(Nuutinen et al., 2010, 2011a,b).
HISTAMINERGIC SYSTEM ALTERATIONS LINKED TO HIGH
RISK ALCOHOL CONSUMPTION
Manymodulatory neurotransmitter systems converge on the same
neurons in the brain. For example, the actions of acetylcholine,his-
tamine,norepinephrine, and serotonin on humanneocortical cells
are similar: they all increase spiking by reducing spike-frequency
adaptation (McCormick and Williamson, 1989). It is thus not sur-
prising that several transmitters or their respective receptor ligands
can have similar effects on neural circuits and behavior. Some
of the important systems in drug abuse include the mesolimbic
dopamine system and corticostriatal and corticoaccumbal gluta-
mate systems (Koob andVolkow, 2010; Kalivas andVolkow, 2011).
All these brain regions are also innervated byhistamine-containing
nerve ﬁbers originating from the posterior hypothalamic tubero-
mamillary nucleus both in rodents and in humans (Panula et al.,
1989; Airaksinen et al., 1991; Jin and Panula, 2005). Following
release, histamine ismainly inactivated bymethylation in the brain
to an inactive metabolite tele-methylhistamine, whereas in the
peripheral organs oxidation by diamino-oxidase is predominant
(Haas and Panula, 2003). Concentrations of tele-methylhistamine
have been shown to correlate well with histamine release in the
brain.Very few studies have directly analyzed the role of histamine
in alcohol-related behaviors in humans, and animal studies have
been carried out only recently. In postmortem analysis, histamine
and tele-methylhistamine, the ﬁrst metabolite of histamine, lev-
els are clearly increased in patients who suffered from extensive
liver cirrhosis following alcohol abuse (Lozeva et al., 2003). The
histamine levels were elevated in both patients with high alcohol
consumption and those with no alcohol use. The mechanism is
thus most likely related to the highly increased levels of neutral
amino acids in the blood circulation, as reviewed earlier for exper-
imental portocaval anastomosis cases (Fogel et al., 2002). In one
study on type 1 (late onset, often females, low degree of associ-
ation with violence) and type 2 (early onset, often males, high
degree of association with violence) alcoholics histamine levels
were signiﬁcantly elevated in the gray matter of type 1 alcoholics
and the levels of tele-methylhistamine were elevated in type 2
alcoholics indicating that histamine turnover is altered (Alakarppa
et al., 2002).
In alcohol-preferring Alko alcohol (AA) rats developed in
Finland in 1960s using a two-bottle choice preference selection
method (Eriksson, 1968) several aminergic systems are abnor-
mal. They have higher tyrosine hydroxylase activity and higher
levels of dopamine and noradrenaline in striatum and limbic
regions (Ahtee and Eriksson, 1975), higher serotonin levels in
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manybrain areas (Ahtee andEriksson,1973),andhigher histamine
and tele-methylhistamine levels in many brain regions than alco-
hol non-preferring Alko non-alcohol (ANA) rats (Lintunen et al.,
2001). Higher tele-methylhistamine levels indicate also higher his-
tamine release in AA than ANA rats. This high histamine content
agrees well with the higher density of histamine-immunoreactive
nerve ﬁbers in many regions of theAA rat brain, including nucleus
accumbens, septal nuclei, and medial preoptic nucleus. Thus, his-
tamine from the other major storage site of brain histamine, mast
cells, is not responsible for the signiﬁcant difference. Receptor
radioligand autoradiography has shown signiﬁcant differences in
histamine H1 receptor binding throughout the brain of AA and
ANA rats. The binding densities in AA rat brain were lower, pos-
sibly as a result of high histamine release induced downregulation
(Lintunen et al., 2001). H3 receptor radioligand binding is lower
in AA than ANA rats in the motor cortex, nucleus accumbens, and
CA1 area of the hippocampus. Although similar systematic studies
have not been carried out in other rat lines selected for high volun-
teer alcohol intake, an analysis of histamine content in the cortex
of the high alcohol preference (HAP) and low alcohol preference
(LAP) rats was not different (Kitanaka et al., 2004). However, the
histamine induced phosphoinositide hydrolysis was signiﬁcantly
lower in HAP than LAP rats (Kitanaka et al., 2004).
Rat lines selected for high alcohol sensitivity (alcohol non-
tolerant, ANT) and low alcohol sensitivity (alcohol tolerant, AT;
Rusi et al., 1977) also show distinct differences in histaminergic
markers in the brain: the ANT rats have reduced histamine levels
in many brain areas, including hypothalamus, septum, cortex, and
hippocampus (Lintunen et al., 2002). The alcohol sensitive ANT
rats also show higher H3 receptor agonist-induced guanosine 5′-
O-(3-[35S]thio)triphosphate binding, indicative of histamine H3
receptor activation, in motor cortex, insula, and caudate-putamen
(Lintunen et al., 2002). The behavioral effects of H3 receptor lig-
ands on these rats have not been tested, but administration of a
suicide inhibitor of the histamine synthesizing enzyme histidine
decarboxylase, α-ﬂuoromethylhistidine (α-FMH), decreases the
performance of these rats in the tilting plane test (Lintunen et al.,
2002) suggesting higher sensitivity to alcohol in the absence of
histamine. Taken together, these results suggest that there are basal
differences in thehistamine systemmarkers in these rat lines.How-
ever, no mutations in genes directly related to histamine synthesis
and metabolism or histamine receptors have been identiﬁed.
HISTAMINE H3 RECEPTOR-MEDIATED REGULATION OF
ALCOHOL DRINKING
Alcohol consumption in experimental animals can be measured
with different types of drinking models. One of the most widely
used paradigms is the two-bottle choice test where animals are
given free-choice access to alcohol and non-alcoholic ﬂuid, typ-
ically water (Green and Grahame, 2008). Alcohol consumption
in this model, however, can be inﬂuenced by other factors than
pharmacological action of alcohol, such as taste and calories. Thus
control studieswith sweet,bitter andhigh caloric ﬂuids are needed.
Using a modiﬁed prolonged 8-week version of the two-bottle
choice we found that the histamine H3 receptor knockout (H3R
KO) mice consumed alcohol at concentrations 10 and 20% sig-
niﬁcantly less than the wild type animals (Nuutinen et al., 2011a;
Table 1). Control studies with bitter quinine and sweet saccharin
revealed no genotype differences. There was no difference between
theH3RKOand controlmice inwater consumption.However, the
food consumption in H3R KO mice was lower than in control ani-
mals leaving us with a question whether the H3R KO mice simply
drink less alcohol since they need less energy?
A more newly described method for alcohol consumption is so
called Drinking in the Dark (DID) method where mice are given
access to alcohol for a short period of time during their active
time of the day (Rhodes et al., 2005). The DID paradigm is a mea-
sure of binge-like alcohol drinking and usually C57BL/6J mice are
used in this paradigm due to their high alcohol consumption. The
method is based on the ﬁnding that rodents consume more alco-
hol during the ﬁrst couple of hours of their active period of the
day (Goldstein and Kakihana, 1977). In line with the two-bottle
choice (dependence-like drinking) study we found that the H3R
KO mice drank less alcohol than control mice when given a 4-h
access to 20% alcohol in the DID model (Nuutinen et al., 2011a;
Table 1). Interestingly, H3R KO mice also consumed less 10%
sucrose than the wild type mice again pointing to the direction
that the lower need of calories could be the underlying reason
for the lower voluntary alcohol consumption in H3R KO mice.
To study this in more detail we used H3R speciﬁc ligands in the
DID model and found that an H3R antagonist ciproxifan dose-
dependently inhibited alcohol drinking andH3R agonist immepip
increased alcohol consumption in wild type mice (Nuutinen et al.,
2011a). Importantly, the consumption of 10% sucrose, very high
in caloric content, was not modiﬁed by ciproxifan or immepip
pretreatment suggesting that other reasons than a altered need for
calories could underlie the change in alcohol consumption follow-
ing modiﬁcation of H3Rs. In agreement with our mouse studies,
Galici et al. (2011) found that an H3R antagonist JNJ-39220675
(1 and 10mg/kg) inhibits alcohol drinking to a similar extent
as naltrexone (5mg/kg) in a two-bottle choice test in selectively
bred alcohol-preferring (P) rats. Interestingly, water consump-
tion was increased by JNJ-39220675 treatment. JNJ-39220675 also
decreased alcohol preference but not alcohol consumption after
a 3-day alcohol deprivation period in P rats. These results sug-
gest that the lack or inhibition of H3R leads to lower alcohol
consumption both in mice and rats.
Alcohol drinking can be also studied using self-administration
paradigms where an operant response, typically a lever press, is
required for the access to drink alcohol. Self-administration mod-
els are thought to gauge better the motivation to drink alcohol
(Green and Grahame, 2008). Operant alcohol self-administration
using oral administration is more commonly used in rats than
in mice since mice do not drink alcohol as readily as the rats do
with the exception of C57BL/6J mouse strain. Already a decade
ago we found that H3R antagonists thioperamide and cloben-
probit (Table 2) dose-dependently (1, 3, 10mg/kg for both drugs)
decrease operant alcohol self-administration in alcohol-preferring
AA rats (Lintunen et al., 2001; Table 1). Treatment with H3R ago-
nist R-α-methylhistamine or H1R antagonist mepyramine did not
affect alcohol self-administration. Recently researchers at John-
son & Johnson tested the H3R antagonist JNJ-39220675 (10 and
30mg/kg) in an operant model and found that it signiﬁcantly
reduced lever presses for alcohol (Galici et al., 2011). Thus, data
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Table 1 | Summary of the alterations in alcohol consumption and reward followed by manipulations of the brain histaminergic system.
Model Animal line/strain Drug treatment Result Reference
Two-bottle choice Alcohol-preferring P rats JNJ-39220675 Decrease in alcohol drinking Galici et al. (2011)
Drinking in the dark C57BL/6J Ciproxifan Lower alcohol consumption Nuutinen et al. (2011a)
Drinking in the dark C57BL/6J Immepip Increased alcohol consumption Nuutinen et al. (2011a)
Two-bottle choice H3R KO mice – Lower alcohol consumption Nuutinen et al. (2011a)
Drinking in the dark H3R KO mice – Lower alcohol consumption Nuutinen et al. (2011a)
Two-bottle choice with 3-day
alcohol deprivation
Alcohol-preferring P rats JNJ-39220675 Decrease in alcohol preference Galici et al. (2011)
Self-administration Alcohol-preferring AA rats Thioperamide Reduced lever presses for alcohol Lintunen et al. (2001)
Self-administration Alcohol-preferring AA rats Clobenprobit Reduced lever presses for alcohol Lintunen et al. (2001)
Self-administration Alcohol-preferring AA rats R-α-methylhistamine Increased lever presses for alcohol Lintunen et al. (2001)
Self-administration Alcohol-preferring AA rats Mepyramine No effect on alcohol lever presses Lintunen et al. (2001)
Self-administration Alcohol-preferring P rats JNJ-39220675 Reduced lever presses for alcohol Galici et al. (2011)
Conditioned place preference H3R KO mice – Inhibition of alcohol-induced place
preference
Nuutinen et al. (2011a)
Conditioned place preference HDC KO mice – Stronger alcohol-induced place
preference
Nuutinen et al. (2010)
Conditioned place preference DBA/2J mice Ciproxifan Inhibition of alcohol-induced place
preference
Nuutinen et al. (2011b)
Conditioned place preference 129/Sv mice Ciproxifan Stronger alcohol-induced place
preference
Nuutinen et al. (2010)
Conditioned place preference DBA/2J mice JNJ-10181457 Inhibition of alcohol-induced place
preference
Nuutinen et al. (2011b)
Conditioned place preference DBA/2J mice Immepip No effect on alcohol-induced place
preference
Nuutinen et al. (2011b)
HDC KO, histidine decarboxylase knockout; H3R KO, histamine H3 receptor knockout.
from oral self-administration studies support the role of H3R
antagonism in suppressing motivation to drink alcohol.
INHIBITORY ROLE OF HISTAMINE IN ALCOHOL-INDUCED
CONDITIONED PLACE PREFERENCE
Alcohol reward and reinforcement can be also studied using
Pavlovian conditioning (Tzschentke, 2007). This approach is
advisable to use in parallel with the drinking studies in order to
exclude intervening variables such as anxiety (Pohorecky, 1991) or
novelty seeking (Cloninger et al., 1988) that might result in altered
alcohol drinking. In our laboratory,we are routinely using anunbi-
ased alcohol-induced conditioned place preference (CPP) model
in mice originally developed and described by Cunningham et al.
(2006). In this model mice are given an alcohol injection paired
with an environmental cue (cage ﬂoor material) for four to eight
times over a periodof 2–3weeks.Onalternatingdayswith the alco-
hol injectionsmice are given vehicle injections pairedwith another
type of ﬂoormaterial.After the conditioningperiodmice are tested
in a preference test where they can choose between the two cage
ﬂoor materials. Place preference is indexed by a signiﬁcant differ-
ence in time spent on one of the conditioning cue ﬂoors between
two groups that have had different cues when conditioned to alco-
hol. In mice lacking the histamine synthesizing enzyme histidine
decarboxylase, the alcohol-evoked CPP was found to be stronger
suggesting that the lack of histamine increases the reward and
reinforcement by alcohol in mice (Nuutinen et al., 2010; Table 1).
Next we used different H3R ligands and found that antagonists
ciproxifan (3mg/kg) and JNJ-10181457 (5mg/kg) totally inhib-
ited the CPP by alcohol in wild type DBA/2J mice (Nuutinen
et al., 2011b). Importantly, H3R antagonist ciproxifan did not
induce place preference or place aversion alone in 129/Sv mice
suggesting that H3R antagonism does not produce place aversion
or preference per se (Nuutinen et al., 2010). However, studies in
other mouse strains and rats and using different H3R antagonists
would be important to conﬁrm that the H3R antagonists do not
have addictive or aversive properties. The H3R agonist immepip
(30mg/kg; Table 2) did not modulate alcohol-induced CPP (Nuu-
tinen et al., 2011b). We think that this was probably due to the
difﬁculty to increase an already strong place preference. When
CPP model was applied to H3R KO mice (C57BL/6J background),
we found a complete lack of alcohol-evoked CPP (Nuutinen et al.,
2011a). In agreement with the alcohol drinking studies these data
suggest that inhibition or lack of H3R leads to loss of alcohol
reward.
MECHANISMS UNDERPINNING THE BEHAVIORAL FINDINGS
Stronger alcohol-inducedCPP inHDCKOmice suggests that hist-
amine could be the key neurotransmitter mediating the inhibitory
effects since the lack of histamine leads to stronger CPP. The
inhibitory effect of H3R antagonists may, however involve other
neurotransmitter systems in addition to histamine due to the het-
eroreceptor function of H3Rs (Schlicker et al., 1994). Interestingly,
brain microdialysis studies have shown that H3R antagonists thi-
operamide and GSK189254 do not affect histamine release in rat
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Table 2 | Examples of drugs used in histamine research and in clinical trials.
Mechanism
of action
Specificity Affinity at human vs.
rat H3 receptor
Use in clinical studies
and possible indication(s)
Reference
ANTAGONISTS
Imidazole-based compounds
Ciproxifan Inverse agonist H3R pK i =7.0, pK i =8.9–9.2 No; experimental drug Ireland-Denny et al. (2001);
Schnell et al. (2010)
Clobenpropit Inverse agonist H3R/H4R pK i =9.1–9.3, pK i =9.1–9.4 No; experimental drug Ireland-Denny et al. (2001);
Schnell et al. (2010)
Thioperamide Inverse agonist H3R/H4R pK i =7.1–7.3, pK i =7.9–8.1 No; experimental drug Ireland-Denny et al. (2001);
Schnell et al. (2010)
Non-imidazole compounds
ABT-239 Inverse agonist H3R pK i =9.4, pK i =8.9 No, experimental drug Esbenshade et al. (2005);
Cowart et al. (2004)
Bavisant (JNJ-31001074) Neutral antagonist? H3R? not disclosed Yes; ADHD, alcoholism Kuhne et al. (2011)
GSK189254 Inverse agonist H3R pK i =9.9; pK i =9.17 Yes, narcolepsy,
hyperalgesia
Medhurst et al. (2007)
JNJ-39220675 Neutral antagonist? H3R K i =1.4 nM, K i =23nM Yes; allergic rhinitis Galici et al. (2011)
Pitolisant (BF2.649) Inverse agonist H3R IC50 =5.3 nM, K i =17nM Yes; excessive daytime
sleepiness, schizophrenia,
epilepsy
Ligneau et al. (2007)
AGONISTS
Immepip partial agonist H3R pK i =9.6, pK i =9.0 No; experimental drug Ireland-Denny et al. (2001)
R-α-methylhistamine agonist H3R pK i =8.9–9.2, pK i =8.6–8.7 No; experimental drug Ireland-Denny et al. (2001);
Schnell et al. (2010)
MODULATORS OF HISTAMINE SYNTHESIS
l-histidine precursor of
histamine
– – No, experimental drug Verdiere et al. (1975)
α-ﬂuoromethylhistidine inhibitor of histidine
decarboxylase
– – No, experimental drug Kollonitsch et al. (1978);
Garbarg et al. (1980)
nucleus accumbens or striatum, the central areas in the regula-
tion of reward and reinforcement (Giannoni et al., 2009, 2010).
Further, dopamine release seems not to be affected either in
these areas. H3R antagonist ABT-239 did not modify dopamine
release in striatum (Fox et al., 2005) and GSK189254 had no
effect on dopamine release in nucleus accumbens (Giannoni et al.,
2010; Table 2). JNJ-39220675 treatment, which was found to
inhibit alcohol drinking and self-administration in rats did not
change dopamine release per se or affect alcohol-induced release
of dopamine (Galici et al., 2011; Tables 1 and 2). However, many
of the above-mentioned drugs as well as many other H3R antago-
nists do increase histamine anddopamine release e.g., in prefrontal
cortex (Brioni et al., 2011), another important area of the meso-
cortico-limbic reward circuit which receives dopaminergic input
from the ventral tegmental area and sends glutamatergic projec-
tions to striatum and nucleus accumbens (Lasseter et al., 2010). In
summary, these results demonstrate that H3R antagonists affect
neurotransmitter release in a region-speciﬁc manner and it seems
that the inhibitory effect of H3R antagonism on alcohol consump-
tion and CPP is likely to result from the effects of these drugs on
neurotransmitter release on brain areas other than striatum and
nucleus accumbens.
Another intriguing mechanism for H3R antagonist-induced
inhibition of alcohol reward is the possible modulation of
postsynaptic dopamine receptor signaling in striatum and nucleus
accumbens.Accumulating evidence suggests thatH3Rs form func-
tional receptor heteromers with dopamine D1 and D2 receptors
(Ferrada et al., 2008, 2009; Moreno et al., 2011) and that speciﬁc
ligands that bind to one of the receptor of the heteromer, will
affect the afﬁnity and signaling of the other. Thus, it is possible
that by binding to postsynaptic H3Rs in striatal areas, the H3R
antagonists might interfere with the enhanced dopaminergic sig-
naling induced by alcohol. We have measured the plasma alcohol
concentrations after H3R ligand administration and found no dif-
ference compared to the corresponding controls thus ruling out
the possibility that H3R ligands would alter alcohol metabolism
(Nuutinen et al., 2011a).
SIMILARITIES AND CONTRASTING FINDINGS WITH OTHER
DRUGS OF ABUSE
Mechanisms leading to addictive behaviors are thought to be
common for all drugs of abuse. In line with the inhibitory role
of histamine in alcohol-induce place preference, a study using
H1 receptor knockout mice found a stronger methamphetamine-
induced CPP than in wild type controls (Takino et al., 2009) and
H3R antagonists thioperamide and clobenprobit reduced amphet-
amine self-administration in rats (Munzar et al., 2004). In contrast
to our alcohol study the CPP for methamphetamine was not
Frontiers in Systems Neuroscience www.frontiersin.org May 2012 | Volume 6 | Article 36 | 4
Nuutinen et al. H3 receptor in alcohol dependence
different in histamine H3R KO mice compared to the control ani-
mals (Okuda et al., 2009). However, the authors used a biased
CPP design (by using one conditioning cue) and place preference
was scored by comparing pre-conditioning and post-conditioning
times. In our laboratory we use two distinct conditioning cues
that are neutral to the mice meaning that they do not prefer either
one of them initially (unbiased design). This is to prevent e.g., the
anxiolytic effect of the drug used that could lead to false-positive
result (Cunningham et al., 2003). Further, studies have shown that
mice change their preference during the conditioning periodwith-
out any reinforcing drugs, so in our paradigm place preference is
scored as time spent in one of the sides of the chamber during
the preference test following the conditioning days (Tzschentke,
2007). We compare this time between two groups that received
alcohol paired with separate cues. Signiﬁcant difference between
the subgroups indicates place preference.
Studies on histamine’s role in morphine dependence are few
but support the inhibitory role of histamine in reward and rein-
forcement. Morphine-induced CPP was attenuated by increasing
histamine levels with l-histidine and potentiated by inhibiting his-
tamine synthesis with α-ﬂuoromethyl histidine in mice (Suzuki
et al., 1995; Table 2). H2 receptor antagonist zolantadine poten-
tiated morphine-induced CPP but also induced place preference
alone accompanied by an increase in dopamine turnover suggest-
ing that it has other targets, possibly dopamine transporter, in
addition to H2Rs. In accordance with our data with alcohol, the
morphine-induced place preferencewas stronger inHDCKOmice
(Gong et al., 2010).
Studies on psychostimulants (cocaine, methamphetamine) are
not in line with the suggested inhibitory role of histamine in
addictive behaviors. In contrast to other ﬁndings in HDC KO
mice (Gong et al., 2010; Nuutinen et al., 2010), no difference in
cocaine-induced CPP was found between the HDC KO and wild
type mice (Brabant et al., 2007). Further, a pretreatment with an
H3R antagonist thioperamide enhanced cocaine’s effects by induc-
ing place preference inmicewith a cocaine dose that did not induce
CPP alone (Brabant et al., 2005). However, thioperamide was later
found to inhibit cocaine metabolism via inhibition of liver CYP-
450 enzymes (Brabant et al., 2009). Amphetamine is also metab-
olized via liver CYP-450 enzymes. Thus, the observations that
H3R antagonists thioperamide and clobenpropit potentiate self-
administration and discrimination of methamphetamine might
be due to inhibition of methamphetamine metabolism by these
imidazole-basedH3R antagonists (Munzar et al., 1998, 2004). Fur-
ther studies with non-imidazole-based H3R compounds and with
knockout/transgenic animal models are needed to reveal the role
of H3R in psychostimulant-induced reward and reinforcement.
Numerous studies on ﬁrst generation H1R antagonists support
the inhibitory role of histamine in reward (for a review see Brabant
et al., 2010). However, these drugs have many targets in addition
to H1Rs such as muscarinic receptors and more importantly, the
dopamine transporter (Shishido et al., 1991; Oishi et al., 1994).
Thus, it is most probably the inhibition of dopamine uptake rather
than H1R blockade that explains why H1R blockers can cause
per se or increase behavioral effects typically induced by addictive
substances.
CONCLUSIONS
There is accumulating evidence from alcohol drinking and
place preference studies suggesting that alcohol reward could be
decreased by treatment with H3R antagonists. More studies are
still needed to test the potential of H3R antagonists to prevent
alcohol withdrawal symptoms or relapse. Cellular and molecu-
lar mechanistic studies are also of great importance in order to
more widely increase our understanding of the complex role of
H3R in addictive behaviors. Studies on alcohol and morphine sug-
gest that targeting brain H3Rs could be a potential means to treat
drug addiction. However, due to conﬂicting ﬁndings with H3R
antagonists in psychostimulant addiction-related behaviors, more
preclinical studies are needed to really show whether H3R antag-
onist would be beneﬁcial in other types of drug addictions. One
of the key questions to be solved is related to the possible differ-
ential expression of H3R in different dopaminergic neurons, and
analysis of direct vs. indirect effects of H3R on dopamine release.
Whereas it seems that histamine H3 receptor is a key element in
alcohol drinking and place preference, the role of histamine in
these behaviors is still unclear. The relative importance of hista-
mine and other transmitters regulated by H3 receptor antagonism
in several alcohol-related behaviors remains to be studied using
speciﬁc tools.
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